Transcatheter seal finance over 1.7 million Euro
Transcatheter Technologies GmbH was founded in 2009 in Regensburg and develops novel medical products to reduce trauma in cardiac surgical interventions. The so-called transcatheter aortic valve prostheses represent leading technology in the field of new generation transcatheter heart valve prostheses. The growing numbers of cardiovascular disease, coupled with an ageing population, has meant an increase in the number of diseased heart valves. The concept is a totally new type of technology and a key advancement attributed to the success of the two company founders Hou-Sen Lim, an engineer from Singapore and Dr. Wolfgang Götz, a heart surgeon from Regensburg. This development makes opening the thorax unnecessary, which is an otherwise costly and burdening operation for patients. What is special about this new procedure is that there is also the opportunity to reposition the valve if necessary following insertion and testing. Currently 350,000 aortic valves are implanted worldwide. This represents a market of more than 700 million Euros. In addition to the existing investors Technologie-Seed-Beteiligungsfonds Bayern GmbH & Co. KG and High-Tech Gründerfonds GmbH, Tubaflex Beteiligungs GmbH, ERP-Startfonds der Kreditanstalt für Wiederaufbau (KFW), Clusterfonds EFRE Bayern and other private investors took part in the new finance round. The finance of over 1.7 million € will serve in the further preclinical development of transcatheter aortic valve prostheses.
For more information see: